1. Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group
   MASAHARU INAGAKI et al, 2016, Molecular and Clinical Oncology CrossRef
2. Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
   Ryosuke Hirano et al, 2016, Asian Pacific Journal of Cancer Prevention CrossRef
3. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
   J.C.-H. Yang et al, 2016, Annals of Oncology CrossRef
4. Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis
   Zuyao Yang et al, 2017, International Journal of Cancer CrossRef
5. Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report
   HIROKO WATANABE et al, 2015, Experimental and Therapeutic Medicine CrossRef
6. A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
   Hisashi Tanaka et al, 2018, Medical Oncology CrossRef
7. Efficacy of gefitinib at reduced dose in EGFR mutant non-small cell lung carcinoma
   Wang Chun Kwok et al, 2019, Anti-Cancer Drugs CrossRef
8. Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay
   Yuta Yamamoto et al, 2018, Journal of Pharmaceutical Analysis CrossRef
9. Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer
   Wenxiong Zhang et al, 2018, Medicine CrossRef
10. Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment
    Saki Tanaka et al, 2024, Cancer Treatment and Research Communications CrossRef
11. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
    Wenxiong Zhang et al, 2018, BMC Cancer CrossRef
12. Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study
    Jing-Ren Ye et al, 2022, Frontiers in Surgery CrossRef
13. Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
    Daniela Cárdenas-Fernández et al, 2023, Therapeutic Advances in Medical Oncology CrossRef